Akrivis Technologies

About:

Akrivis Technologies is a biopharmaceutical company committed to the early detection, diagnosis and treatment of life-threatening diseases.

Website: http://www.akrivis.com

Twitter/X: akrivistech

Top Investors: Massachusetts Life Sciences Center, North Shore InnoVentures, MassChallenge, IDEA: Northeastern University's Venture Accelerator

Description:

Akrivis Technologies is a privately held biopharmaceutical company committed to the early detection, diagnosis, and treatment of serious and life-threatening diseases based on its patented Z-TECTTM technology platform. Their main asset is its proprietary Z–TECTTM Technology Platform, which has been shown to provide high sensitivity detection and accurate quantification of biomolecules down to the zeptomole range (10E–21 moles), therefore potentially allowing the detection of less than a thousand individual molecules. In addition to supporting in vitro and in vivo diagnostics, Z–TECTTM can also serve as a novel platform for the targeted delivery of a high payload of radio-or chemo-therapeutic drugs for cancer treatment. Potentially enabling far safer and more efficacious targeted delivery therapies, Z–TECTTM could also have a major impact on the emerging field of “Theranostics”, which simultaneously combines diagnostics and therapy.